Shanghai Jiao Tong University

About: Shanghai Jiao Tong University is a education organization based out in Shanghai, Shanghai, China. It is known for research contribution in the topics: Population & Cancer. The organization has 157524 authors who have published 184620 publications receiving 3451038 citations. The organization is also known as: Shanghai Communications University & Shanghai Jiaotong University.

Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial

Abstract: Summary Background Icotinib, an oral EGFR tyrosine kinase inhibitor, had shown antitumour activity and favourable toxicity in early-phase clinical trials. We aimed to investigate whether icotinib is non-inferior to gefitinib in patients with non-small-cell lung cancer. Methods In this randomised, double-blind, phase 3 non-inferiority trial we enrolled patients with advanced non-small-cell lung cancer from 27 sites in China. Eligible patients were those aged 18–75 years who had not responded to one or more platinum-based chemotherapy regimen. Patients were randomly assigned (1:1), using minimisation methods, to receive icotinib (125 mg, three times per day) or gefitinib (250 mg, once per day) until disease progression or unacceptable toxicity. The primary endpoint was progression-free survival, analysed in the full analysis set. We analysed EGFR status if tissue samples were available. All investigators, clinicians, and participants were masked to patient distribution. The non-inferiority margin was 1·14; non-inferiority would be established if the upper limit of the 95% CI for the hazard ratio (HR) of gefitinib versus icotinib was less than this margin. This study is registered with ClinicalTrials.gov, number NCT01040780, and the Chinese Clinical Trial Registry, number ChiCTR-TRC-09000506. Findings 400 eligible patients were enrolled between Feb 26, 2009, and Nov 13, 2009; one patient was enrolled by mistake and removed from the study, 200 were assigned to icotinib and 199 to gefitinib. 395 patients were included in the full analysis set (icotinib, n=199; gefitinib, n=196). Icotinib was non-inferior to gefitinib in terms of progression-free survival (HR 0·84, 95% CI 0·67–1·05; median progression-free survival 4·6 months [95% CI 3·5–6·3] vs 3·4 months [2·3–3·8]; p=0·13). The most common adverse events were rash (81 [41%] of 200 patients in the icotinib group vs 98 [49%] of 199 patients in the gefitinib group) and diarrhoea (43 [22%] vs 58 [29%]). Patients given icotinib had less drug-related adverse events than did those given gefitinib (121 [61%] vs 140 [70%]; p=0·046), especially drug-related diarrhoea (37 [19%] vs 55 [28%]; p=0·033). Interpretation Icotinib could be a new treatment option for pretreated patients with advanced non-small-cell lung cancer. Funding Zhejiang Beta Pharma (China), the Chinese National Key Special Program for Innovative Drugs, the 863 Project, and Zhejiang Provincial Key Special Program.

Bankruptcy Classification Errors in the 1980s: An Empirical Analysis of Altman and Ohlson's Models

Abstract: Empirical accounting researchers often use Altman's (1968) and Ohlson's (1980) bankruptcy prediction models as indicators of financial distress. While these models performed relatively well when they were estimated, we show that they do not perform as well in more recent periods (in particular, the 1980s), even when the coefficients are re- estimated. When we compare the performance of Ohlson's original model to our re-estimated version of his model and to that of Altman's original and re-estimated models, we find that Ohlson's original model displays the strongest overall performance. Given that Ohlson's original model is frequently used in academic research as an indicator of financial distress, its strong performance in this study supports its use as a preferred model.

Three-column fixation for complex tibial plateau fractures.

Abstract: Objectives:1) To introduce a computed tomography-based “three-column fixation” concept; and 2) to evaluate clinical outcomes (by using a column-specific fixation technique) for complex tibial plateau fractures (Schatzker classification Types V and VI).Design:Prospective cohort study.Setting:Level 1

Accelerated proximal gradient methods for nonconvex programming

Abstract: Nonconvex and nonsmooth problems have recently received considerable attention in signal/image processing, statistics and machine learning. However, solving the nonconvex and nonsmooth optimization problems remains a big challenge. Accelerated proximal gradient (APG) is an excellent method for convex programming. However, it is still unknown whether the usual APG can ensure the convergence to a critical point in nonconvex programming. In this paper, we extend APG for general nonconvex and nonsmooth programs by introducing a monitor that satisfies the sufficient descent property. Accordingly, we propose a monotone APG and a nonmonotone APG. The latter waives the requirement on monotonic reduction of the objective function and needs less computation in each iteration. To the best of our knowledge, we are the first to provide APG-type algorithms for general nonconvex and nonsmooth problems ensuring that every accumulation point is a critical point, and the convergence rates remain O(1/k2) when the problems are convex, in which k is the number of iterations. Numerical results testify to the advantage of our algorithms in speed.

Nanosheet-constructed porous TiO2-B for advanced lithium ion batteries.

Abstract: Hierarchical porous TiO(2)-B with thin nanosheets is successfully synthesized. TiO(2)-B polymorph ensures fast insertion of Li-ion due to its pseudocapacitive mechanism. The thin nanosheet walls with porous structure allow exposure to electrolytes for facile ionic transport and interfacial reaction. The joint advantages endow this material with high reversible capacity, excellent cycling performance, and superior rate capability.